Dr. Berry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St Fl 8
Boston, MA 02114Phone+1 617-724-3914
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 2006 - 2009
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2005 - 2006
Northwestern University The Feinberg School of MedicineClass of 2005
Certifications & Licensure
MA State Medical License 2009 - 2025
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers Start of enrollment: 2011 Nov 01
- Gilenya in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
- Longitudinal Study of Outcomes Measures in ALS Trials Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- An Expanded Access Protocol of RNS60 in Amyotrophic Lateral Sclerosis.Grace Addy, Erica Scirocco, Dario Gelevski, Margot Rohrer, Aimee Roderick
Muscle & Nerve. 2025-03-21 - Clinician Perspectives Highlight the Need for Early Dyadic Coping Skills for People Living With Amyotrophic Lateral Sclerosis.Christina L Rush, Chris Lyons, Jenna Gittle, Morgan Seward, Jennifer Scalia
Journal of Pain and Symptom Management. 2025-03-01 - 2 citationsCNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial., James D Berry, Nicholas J Maragakis, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17
Press Mentions
Healey & AMG Center for ALS Launches ALS MyMatch: An Early Phase Biomarker Driven Trial ProgramFebruary 25th, 2025- Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Disease Progression with RADICAVA® (Edaravone) in ALSJanuary 29th, 2025
- Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS AssociationNovember 19th, 2024
- Join now to see all
Grant Support
- An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with PridopidineMASSACHUSETTS GENERAL HOSPITAL2023–2027
- A diagnostic biomarker for amyotrophic lateral sclerosisJOHNS HOPKINS UNIVERSITY2023–2027
- Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral SclerosisMASSACHUSETTS GENERAL HOSPITAL2023–2026
- Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral SclerosisMASSACHUSETTS GENERAL HOSPITAL2023–2026
- Access for All in ALS (ALL ALS) East Clinical Coordinating CenterMASSACHUSETTS GENERAL HOSPITAL2023–2025
- Access for All in ALS (ALL ALS) East Clinical Coordinating CenterMASSACHUSETTS GENERAL HOSPITAL2023–2025
- An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral SclerosisMASSACHUSETTS GENERAL HOSPITAL2022–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
